Anti-CD47 [A4]
Catalogue Number: AB01061-34.11-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | IAP; CD47 antigen; CD47 glycoprotein; Integrin-associated protein; Leukocyte surface antigen CD47; MER6; OA3; Rh-related antigen |
| Shipping Condition: | Blue Ice |
| Unit(s): | 100 ug |
| Host name: | Camelid |
| Clone: | A4 |
| Isotype: | |
| Immunogen: | This mouse CD47-specific antagonist nanobody was raised by immunising alpacas with the extracellular Ig-like V-type domain (ECD) of mouse CD47. Subsequently, peripheral blood lymphocytes (PBLs) were isolated from immunized alpacas, and the extracted RNA was used to construct a VHH phage display library. The antibody was generated by panning against the mouse CD47 ECD. |
| Application: | FC, FA, Blk, InVitroA, InVivoA, Ant |
Additional Text
Gene Name
CD47
Uniprot ID
Q61735
Gene ID
16423
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Application Notes
This nanobody has been shown to bind with high affinity and specificity to mouse CD47, as characterized by SPR and FACS (Sockolosky et al 2016). In vitro functional assays suggest that this nanobody potently blocks SIRPα binding to tumor cell-surface CD47, while broadly recognizing mouse hematopoietic and red blood cells without causing erythropenia (Sockolosky et al 2016). The original nanobody was reported to bind immobilized mouse CD47 with a binding affinity of Kd= ~12 pM (Sockolosky et al 2016). Consistent with its species-specific binding properties, this nanobody has been found not to influence human macrophage phagocytosis of human tumor cells. Furthermore, this nanobody has been used to investigate the biological consequences of antagonizing CD47 in syngeneic mouse disease models (Sockolosky et al 2016).
AB01061-34.11 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations